A panel of five lncRNAs, low expressed in tumor (LET), plasmacytoma variant translocation 1 (PVT1), promoter of CDKN1A antisense DNA damage activated RNA (PANDAR), phosphatase and tensin homolog pseudogene 1 (PTENP1), and linc00963, was able to successfully discriminate non-cancer from RCC patients (AUC = 0.823) and retained their diagnostic ability throughout the different clinical TNM stages, also indicating their utility as early markers for RCC (Wu et al., 2016). Here, PVT1 is linked to neoplasm.